To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
51 Current news of Carl Zeissrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Long-term prospects for KIT carve-outs
ZEISS plans to build a new shared innovation hub on the north campus of the Karlsruhe Institute of Technology (KIT). Construction is scheduled to begin in early 2018; the €30 million hub will cover 12,000 square meters. With the ZEISS Innovation Hub, the global technology leader in optics and ...
World market leaders combine strengths in ADAMOS
Through the joint venture ADAMOS (ADAptive Manufacturing Open Solutions), DMG MORI, Dürr, Software AG and ZEISS as well as ASM PT are establishing a strategic alliance for the future topics of Industrie 4.0 and the Industrial Internet of Things (IIoT). Germany’s first alliance of well-known ...
Acquisition of Veracity Innovations, LLC
ZEISS continues to lead in advancing the digitalization of eye care with the acquisition of Veracity Innovations, LLC, led by renowned ophthalmologists Dr. Kyle Smith and Dr. Kerry Solomon. By intelligently synthesizing relevant critical data for specific clinical applications across the spectrum ...
Executive Board Members Monz and Metz will also continue
The Supervisory Board of Carl Zeiss AG has decided to continue the appointment of Dr. Michael Kaschke as President & CEO until 30 June 2020. Kaschke joined the ZEISS Group 25 years ago and has served on the Executive Board since 2000. He has been President & CEO of Carl Zeiss AG since 2011. The ...
Demand for digital solutions increases
The ZEISS Group had a very successful end to the first six months of fiscal year 2016/17 (ended 31 March) and saw its revenue rise by 10 percent to EUR 2.550 billion (1st half of 2015/16: EUR 2.322 billion). At EUR 384 million, the earnings before interest and tax (EBIT) were significantly higher ...
VSY Biotechnology B. V. (VSY) has, amongst others, filed an opposition againstCarl Zeiss Meditec A.G.’s (Zeiss) European patent EP 2 377 493 B1 “Method for manufacturing aphakic intraocular lens” (EP’493) with the European Patent Office (EPO) on May 6, 2016. Zeiss acquired EP’493 from the German ...
A new agreement between the Carl R. Woese Institute for Genomic Biology (IGB) at the University of Illinois at Urbana-Champaign and ZEISS has named the Core Facilities at IGB as an official ZEISS labs@location Partner. The model facility will allow researchers from around the U.S. to test-drive ...
The patent protects a special aphakic intraocular lens (IOL), with which light can be focused on three focal points (near, intermediate and distance vision). The patented trifocal lens reduces the impact of pupil shrinkage and lens eccentricity. VSY Biotechnology BV and its exclusive supplier ...
Positive revenue and earnings trend – further growth in recurring revenue
Carl Zeiss Meditec AG has brought financial year 2015/16 to a successful close with further growth: Revenue increased by 4.6 percent (adjusted for currency effects: 2.7 percent) to €1,088.4m. Earnings before interest and taxes (EBIT) rose to €154.3m (prior year: €130.6m). The EBIT margin ...
ZEISS will support innovative research projects at the Swiss Federal Institute of Technology in Lausanne (École polytechnique fédérale de Lausanne, abbr. EPFL). The company will make one million euros available for new research projects in key technology fields such as biomedical research, ...